Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 7, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Salim Syed Reiterated (ATRA) at Strong Buy and Held Target at $775 on, Feb 7th, 2023
Salim Syed of Mizuho, Reiterated "Atara Biotherapeutics, Inc." (ATRA) at Strong Buy and Held Target at $775 on, Feb 7th, 2023.
Salim has made no other calls on ATRA in the last 4 months.
There is 1 other peer that has a rating on ATRA. Out of the 1 peers that are also analyzing ATRA, 0 agree with Salim's Rating of Hold.
This is the rating of the analyst that currently disagrees with Salim
- Tony Butler of "EF Hutton" Initiated at Strong Buy and Held Target at $625 on, Thursday, January 5th, 2023
